Physician-patient communication and shared decision-making approaches in myeloproliferative neoplasm care. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...

MPN-U patients exhibit lower platelet counts and higher venous thrombosis rates compared to ET, with thrombosis often occurring at atypical sites. Genetic analysis shows JAK2 mutations are more common ...

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...

BOZEMAN, MONTANA, USA, February 1, 2024 /EINPresswire.com/ -- Alercell, Inc., an innovative leader in molecular diagnostics, has recently unveiled its latest ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 ...